Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Hordenine

Plain-language summaryIntrigue 35 / 100

Hordenine (N,N-dimethyl-tyramine) is a phenethylamine alkaloid found in germinating barley and several cacti. It is a weak MAO-B inhibitor and a weak monoamine reuptake inhibitor, and the combination slows the breakdown of dopamine and short-lived trace amines like beta-phenylethylamine (PEA). The supplement use angle is to pair it with PEA, where the MAO-B inhibition extends PEA’s normally minutes-long duration into something noticeable. Plasma half-life is one to two hours. The actual pharmacological effects in humans at supplement doses are modest, and most enthusiasm comes from extrapolation rather than human trials. Botanical MAO-B reference compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

22/100

Weak botanical MAO-B inhibitor with a narrow PEA-extension niche and no compelling independent research case

Look, hordenine isn’t a bad compound. It’s just not an interesting one, and those are different problems. N,N-dimethyl-tyramine has been in the literature long enough that its pharmacological ceiling is well-understood, and that ceiling is low. Weak MAO-B inhibition, weak monoamine reuptake inhibition, plasma half-life around 1-2 hours. Nothing there surprises anyone who’s read the trace amine literature from the last two decades.

The mechanism isn’t without logic. MAO-B catabolizes beta-phenylethylamine aggressively, which is why PEA’s endogenous half-life is measured in minutes despite its potent monoaminergic effects. Hordenine slows that degradation, so stacking it with PEA extends PEA’s window of action. That’s the entire scientific case for hordenine as a research-relevant compound, and its essentially a delivery-extension story, not a primary mechanism story. We like that the trace amine/TAAR1 space has gotten serious attention in the last decade, but hordenine isnt the probe you reach for when you want to study it properly.

On differentiation, hordenine loses badly to actual pharmacological MAO-B inhibitors. Selegiline is selective, potent, and has a massive preclinical and clinical literature. Rasagiline similarly. Safinamide adds a sodium channel component that gives it real mechanistic depth. Hordenine against those tools is like using a butter knife for something that needs a scalpel. Its botanical origin is sometimes cited as a feature, and we suppose it is if you’re running naturalistic formulation studies, but that’s a thin reason to prioritize it on a serious bench program.

Evidence quality is limited. Theres reasonable in vitro and rodent preclinical data supporting the MAO-B inhibitory activity, but multi-lab replication is sparse and human-facing data at supplement-relevant doses is essentially observational and anecdotal. The pharmacodynamic effects in humans are described uniformly as modest, which is consistent with the weak binding affinities measured in vitro. No robust phase 1 or 2 clinical work anchors the human translation.

Honestly, the only scenario where hordenine earns a place in an active research program is if the program specifically needs a botanical source of mild MAO-B modulation, or if PEA pharmacokinetics are the direct object of study. Both are narrow. Outside those cases, its a mature, well-understood adjunct compound that doesn’t open new questions, doesnt offer unique probe value, and doesn’t differentiate from better tools. A serious investigator would deprioritize this in favor of almost anything else in the phenethylamine or trace amine space.

Novelty

22

Mechanism promise

22

In-category differentiation

18

Evidence quality

25

Translational signal

20

Research bench value

28

Rationale Hordenine scores low across every axis because it’s a decades-old, well-characterized botanical alkaloid whose pharmacology is unremarkable: weak MAO-B inhibition, weak monoamine reuptake inhibition, modest human effect size at supplement doses, and zero differentiation from superior pharmacological tools in its class. Its only credible research angle is as a botanical adjunct extending PEA’s short half-life, which is a narrow probe application rather than a standalone research program.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenethylamine MAO-B inhibitor / mild stimulant

N,N-dimethyl-tyramine; a phenethylamine alkaloid found in barley sprouts; a weak MAO-B inhibitor used as a stimulant adjunct.

Abstract

Hordenine (N,N-dimethyl-tyramine; CAS 539-15-1; molecular formula C10H15NO; molecular weight 165.23) is a phenethylamine alkaloid found in germinating barley (Hordeum vulgare) and several cacti. The compound is a weak monoamine oxidase B inhibitor and a weak monoamine reuptake inhibitor; the combined activity slows the degradation of dopamine and trace amines including beta-phenylethylamine (PEA), prolonging their action. Used as a supplement, particularly in combination with PEA where the MAO-B inhibition extends PEA’s normally minutes-long duration. Plasma half-life is approximately 1 to 2 hours. The pharmacological effects in humans at supplement doses are modest. Used as a botanical MAO-B inhibitor in research and in supplement formulations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-385Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Org-26576

Plain-language summaryIntrigue 40 / 100

Org-26576 is a sulfonamide AMPA potentiator developed at Organon. Phase 2 trials investigated it in major depressive disorder and ADHD. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

39/100

Discontinued Merck ampakine with modest Phase 2 signal and limited bench accessibility

AMPA receptor positive allosteric modulators have a genuinely compelling theoretical basis. By slowing channel deactivation and desensitization, they amplify glutamatergic throughput, drive BDNF expression, and modulate synaptic plasticity in ways that NMDA-targeted compounds simply can’t replicate. The mechanism is interesting, the rationale for depression and cognitive enhancement is plausible, and Org-26576 at least made it further through clinical development than most ampakines. Organon built the program, Schering-Plough inherited it, Merck finished it, and then walked away. That arc matters.

Here’s the thing about the AMPA PAM class: it has a long, frustrating history of preclinical promise colliding with clinical disappointment. CX516, CX717, farampator, LY404187 and a dozen others all generated real excitement in the late 1990s through mid-2000s, showed plausible Phase 1 tolerability, and then produced Phase 2 data described in almost identical language to whats in Org-26576’s dossier: modest cognitive endpoint improvements, no adverse signal. In pharmaceutical development that’s a polite way of saying the delta wasn’t there. When a well-resourced pharma group has already invested in full IND-enabling studies and a Phase 2 execution and still walks away, the independent research community is left with a thin published evidence base and whatever can be reconstructed from conference abstracts.

The sulfonamide scaffold is a genuine chemical differentiator. Org-26576 is not just a CX-class analog; the sulfone headgroup changes the binding geometry and potentially the kinetic profile of AMPA channel modulation in ways that aren’t fully worked out in the public literature. For a group specifically investigating structure-activity relationships across AMPA PAM chemotypes, or trying to understand whether kinetic selectivity differences between ampakine classes have functional consequences, this compound represents a well-defined clinical-stage data point. It cleared human safety. That’s real. It’s also about the extent of the positive case.

Sourcing is a serious obstacle. The compound is rarely available in research-chemical-grade markets, which means bench accessibility is low and reproducibility across labs is essentially hypothetical. Researchers who want an AMPA PAM probe with documented methodology would typically reach for farampator, which has more published protocol support, or look at the newer BNT-III class compounds generating current literature. We think the under-characterized sulfonamide angle is the only genuine hook here, and it’s a narrow one.

Honestly, this scores where it does because the class is mature, the clinical outcome was modest, the compound is hard to source, and the evidence base is largely gated behind Merck’s development files. Interesting chemistry in an underdelivering class isnt the same as a compelling research target.

Novelty

38

Mechanism promise

57

In-category differentiation

30

Evidence quality

40

Translational signal

35

Research bench value

28

Rationale Org-26576 earns modest scores across the board: the sulfonamide AMPA PAM scaffold has chemical interest but the class has a consistent history of clinical underdelivery, and Merck’s discontinuation leaves the evidence base thin and sourcing nearly nonexistent for independent labs. Mechanism score is the brightest spot; differentiation and bench value are both dragged down by limited availability and a crowded class where better-characterized probes already exist.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sulfonamide AMPA potentiator

An Organon/Merck ampakine that reached Phase 2 in major depressive disorder.

Abstract

Org-26576 is a sulfonamide-class AMPA receptor positive allosteric modulator developed by Organon (subsequently Schering-Plough, Merck) for cognitive enhancement in major depressive disorder and other indications. The compound advanced through Phase 2 trials with results consistent with the ampakine class profile (modest cognitive endpoint improvements, no adverse signal). The development program was discontinued under Merck. Pharmacokinetics: plasma half-life approximately 5 hours; oral bioavailability adequate. The compound is rarely available in research-chemical-grade markets.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-060Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
MK-677 (Ibutamoren)

Plain-language summaryIntrigue 72 / 100

MK-677 (Ibutamoren) is a small-molecule growth hormone releaser that mimics ghrelin. Unlike GHRPs, it is orally active because it is not a peptide. It produces sustained growth hormone elevation, increased appetite, and improved sleep, often used in research contexts as an oral GH releaser. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

48/100

Oral GH secretagogue that defines its niche but Phase 3 failure and 1990s vintage cap the ceiling

Look, MK-677 occupies a genuinely interesting position in the GH secretagogue class: it’s the compound that answered the question “can you get sustained GH elevation orally, once a day, without injections?” The answer is yes, and that answer still matters to investigators who want to study GH/IGF-1 biology in models that don’t require daily subcutaneous dosing. Merck’s program produced real clinical data: the Chapman et al. JCEM studies showed sustained IGF-1 elevation and lean body mass increases over 12 to 24 months in elderly subjects, which is a rare duration for a secretagogue trial and a genuinely useful data set.

The mechanism is well-defined: MK-677 is a high-affinity ghrelin receptor (GHS-R1a) agonist. It mimics ghrelin’s pulsatile GH secretagogue effect while bypassing the peptide limitations that make most GHRPs injection-dependent. The oral bioavailability is the real story here. Compared to ipamorelin or GHRP-6, which have essentially identical receptor pharmacology but require parenteral delivery, MK-677 lets you run longer-duration protocols without compliance issues. Thats a meaningful tool advantage that nothing else in the class currently matches.

What we don’t like: this is a 1990s Merck compound. The mechanism is single-receptor and well-understood. The Phase 3 trial in GH-deficient elderly patients was disappointing enough that the program was shelved, which is a real mark against it. The Phase 3 failure doesn’t invalidate the Phase 2 biology, but it does tell you the clinical hypothesis didn’t hold at the population level for the intended indication. The water retention and insulin resistance signal at sustained doses also complicates interpretation in any metabolic research context where you need a clean readout.

Honestly, MK-677 is more useful as a research tool than as a frontier compound. If you’re studying the GH axis, IGF-1-dependent anabolism, or ghrelin signaling and body composition, MK-677 gives you sustained once-daily GHS-R1a activation that no peptide GHRP can match practically. There’s also ongoing interest in sleep architecture effects, since GHS-R1a expression in hypothalamic circuits appears to influence slow-wave sleep independent of GH secretion. That secondary biology is arguably the fresher angle right now, though the evidence is early.

But lets be honest about the ceiling. A compound developed in the early 1990s with a well-characterized single receptor target and a failed Phase 3 is not where the frontier is. It scores in the lower established-active range: genuinely useful, real clinical data, best-in-class on oral delivery, but not a primary target for investigators chasing the next major finding in this space.

Novelty

32

Mechanism promise

42

In-category differentiation

60

Evidence quality

52

Translational signal

48

Research bench value

62

Rationale MK-677 is the only orally bioavailable non-peptide ghrelin receptor agonist with genuine Phase 2 clinical data, giving it real bench value for GH/IGF-1 axis research. A failed Phase 3, well-characterized single-receptor mechanism, and three decades of age keep novelty and translational scores firmly in the established range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Orally active non-peptide ghrelin receptor agonist

A Merck-developed orally bioavailable non-peptide ghrelin receptor agonist that produces sustained GH and IGF-1 elevation with once-daily oral dosing.

Abstract

MK-677 (Ibutamoren; CAS 159752-10-0; molecular formula C27H36N4O5S; molecular weight 528.66) is a non-peptide ghrelin receptor agonist developed by Merck in the 1990s. Unlike the peptide GHRPs, MK-677 is orally bioavailable and produces sustained GH and IGF-1 elevation over 24 hours with once-daily dosing. Phase 2 trials in elderly subjects showed sustained increases in GH, IGF-1, and lean body mass over 12 to 24 month treatment periods. The compound did not advance to FDA approval; the program was deprioritized after disappointing Phase 3 results in the GHD elderly population. The compound is sold as a research chemical/dietary supplement in some markets, though FDA has issued warnings against its sale as a supplement. Pharmacokinetics: plasma half-life 4 to 6 hours; high oral bioavailability; hepatic CYP3A4 metabolism. Doses are typically 10 to 25 mg orally once daily, usually at bedtime to align with the natural GH pulse. Adverse events include increased appetite, water retention, and modest insulin resistance with chronic high-dose use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-078Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Setmelanotide

Plain-language summaryIntrigue 84 / 100

Setmelanotide, sold as Imcivree, is a selective MC4 receptor agonist approved by the FDA for genetic obesity caused by mutations in the leptin-melanocortin pathway. It is one of the first targeted obesity drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

63/100

Precision MC4 agonist with clean rare-disease evidence, limited to genetic responder populations

Look, setmelanotide is one of the more elegant precision-medicine stories in obesity research, and we mean that sincerely. The compound targets MC4 receptors in the hypothalamus, sitting downstream of a well-characterized signaling cascade: leptin binds LEPR, activates POMC neurons, which release alpha-MSH, which hits MC4 to suppress appetite and increase energy expenditure. In patients with loss-of-function mutations in POMC, LEPR, or PCSK1, that pathway breaks at one of its upstream nodes. Setmelanotide sidesteps the break entirely, stepping in at MC4 directly. Its roughly 5 nM affinity for MC4 with meaningful selectivity over MC1 and MC3 is what makes it clinically workable – earlier nonselective melanocortin agonists like bremelanotide and melanotan II couldn’t avoid MC1/MC3-related side effects including pigmentation changes and nausea.

The clinical story is solid. The Rhythm Pharmaceuticals pivotal trials in POMC-deficient and LEPR-deficient patients showed 10-13% body weight reduction over roughly one year, effect sizes you genuinely don’t see that often in rare disease work. The Bardet-Biedl syndrome approval followed in 2022, extending the indication to a syndromic ciliopathy where MC4 pathway disruption is one piece of a larger genetic picture. Phase 3 data for both indications hold up to scrutiny – small N, obviously, because the populations are rare by definition, but the effect sizes are large enough that statistical confidence isnt the limiting concern.

Here’s the thing though: that genetic precision is also what limits the score. Outside the defined responder populations, setmelanotide basically doesn’t work. Trials in common polygenic obesity came up essentially empty. So as a research target for investigators exploring obesity broadly, it’s useful mainly as a proof-of-concept that the MC4 pathway is load-bearing in genetically intact humans – which, sure, thats interesting, but the therapeutic utility narrows sharply once you leave rare genetic disease territory. The novelty window closed fast once the pivotal data were published; the mechanism is now well-understood and the approved populations are clearly delineated.

The ongoing expansion into craniopharyngioma-associated hypothalamic obesity and SRC1 haploinsufficiency is worth watching. These are conditions where MC4 pathway disruption happens through tumor damage or partial LOF rather than complete null mutations, and a positive readout in those spaces would meaningfully widen the relevant population. There are active trials as of 2024-2025. Bench value is real but specialized: setmelanotide is an excellent probe for dissecting MC4-dependent appetite suppression from MC4-independent energy expenditure effects, and for delineating downstream hypothalamic effectors in genetic obesity models. For labs actively working on melanocortin pathway biology, we think it’s close to indispensable. For everyone else, the utility is considerably more limited than the approval history might initially suggest.

Novelty

55

Mechanism promise

60

In-category differentiation

68

Evidence quality

72

Translational signal

68

Research bench value

58

Rationale FDA-approved in 2020 and 2022 for genetically defined obesity syndromes with large effect sizes in well-characterized responder populations; the precision of the genetic-responder model is simultaneously its scientific strength and its research ceiling, constraining broader novelty and translational reach outside rare disease territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective MC4 receptor agonist

An FDA-approved (2020) selective MC4 receptor agonist (Imcivree) for genetic obesity disorders (POMC, LEPR, PCSK1 deficiency).

Abstract

Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; molecular weight 1117.34) is a selective MC4 receptor agonist developed by Rhythm Pharmaceuticals and approved by the FDA in 2020 for chronic weight management in adults and children aged 6 years and older with obesity due to proopiomelanocortin (POMC), leptin receptor (LEPR), or PCSK1 deficiency. The compound is also approved for Bardet-Biedl syndrome obesity (2022). Mechanism is selective MC4 agonism in the hypothalamus, restoring downstream signaling in the leptin-melanocortin pathway disrupted by upstream genetic defects. The drug produces clinically meaningful weight loss in the genetically defined responder populations but minimal effect in non-genetic obesity. Pharmacokinetics: subcutaneous administration daily; plasma half-life approximately 11 hours. Approved doses are 2 to 3 mg once daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-094Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lion’s Mane (Hericium erinaceus)

Plain-language summaryIntrigue 65 / 100

Lion’s mane mushroom (Hericium erinaceus) contains hericenones and erinacines that promote nerve growth factor (NGF) production. Used as a nootropic and being studied for cognitive decline. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Medicinal mushroom / NGF inducer

A medicinal mushroom containing hericenones and erinacines with documented NGF induction and modest cognitive enhancement in mild cognitive impairment.

Abstract

Hericium erinaceus (Lion’s Mane mushroom) is a medicinal mushroom containing hericenones (in the fruiting body) and erinacines (in the mycelium), both classes of which induce nerve growth factor (NGF) expression in vitro and in vivo. NGF is critical for cholinergic neuron survival and function. A small randomized trial in Japanese subjects with mild cognitive impairment showed cognitive endpoint improvements with chronic Lion’s Mane supplementation (3 grams per day for 16 weeks). Additional studies suggest peripheral nerve regeneration applications and modest anxiolytic effects. The compound is sold as both fruiting body extracts and mycelium-on-grain products; the latter contains erinacines but also significant residual grain (rice, oats) which has led to controversy about active constituent content. Doses are typically 500 mg to 3 grams per day of the fruiting body extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-110Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymulin

Plain-language summaryIntrigue 50 / 100

Thymulin is a 9-amino-acid zinc-dependent thymic hormone that regulates T-cell development. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

A 1970s thymic nonapeptide with legitimate immunology history but limited current research priority

Thymulin has been in the literature for over fifty years, which should tell you something. Bach and Goldstein’s groups first isolated it from thymic epithelial extracts in the 1970s, and while the zinc-dependent activation story is genuinely interesting biochemistry, the compound hasn’t really moved the needle in the decades since. Thats a long time to stay at the preclinical fringe.

Here’s the thing about the mechanism: thymulin requires bound zinc to be biologically active, and the apopeptide alone does essentially nothing. The Zn-thymulin complex is the active form, which creates a practical wrinkle that’s underappreciated in the peptide community. That zinc-dependency makes it a defensible model for studying metallopeptide pharmacology, and we think that’s actually its most legitimate research use in 2025. But the biology of thymic epithelial signaling and T-cell differentiation is well-mapped territory. There’s nothing paradigm-altering in the mechanism here.

The differentiation problem is real and it’s the biggest drag on the score. Thymosin alpha-1, the better-known thymic peptide, has reached regulatory approval in multiple jurisdictions and carries a substantially larger clinical trial base. If your research program touches thymic immunomodulation or infection adjunct applications, thymulin is not the first compound you’d reach for. It competes in a class where thymosin alpha-1 clearly outpoints it on evidence and thymosin beta-4 fragments have more active current interest. One of several, not the obvious choice.

The evidence base earns some credit. Multi-decade preclinical work across multiple independent labs is worth something, and it puts thymulin above single-consortium peptides like Epitalon. There’s limited Phase 2 data in chronic infections and some autoimmune contexts, which is real. But limited Phase 2 data and no regulatory follow-through after fifty years is a signal. The Eastern European literature cluster pattern that plagues other thymic peptides shows up here too, and it introduces replication concerns you cant fully dismiss.

What we do find interesting is the aging-thymus angle. Thymic involution is a genuine biological problem, thymulin levels decline with age alongside thymic output, and theres a plausible rationale for studying thymulin or synthetic analogs as probes of age-related immune deterioration. Some recent work from Brazilian groups on nonapeptide analogs with modified zinc-chelating residues is actually more compelling than the parent compound. That derivative work is worth watching; the original compound less so.

Honestly, for most investigators in 2025, thymulin is background reading rather than an active target. It earns its place in a complete immunology reference library, and it’s useful context when studying thymic peptides as a class. But its not a priority bench object unless you already have a thymus-specific program and need the original compound as a reference standard.

Novelty

28

Mechanism promise

38

In-category differentiation

25

Evidence quality

40

Translational signal

30

Research bench value

45

Rationale Thymulin is a mature compound with well-established mechanism and multi-decade multi-lab preclinical work, but limited clinical translation and clear competition from thymosin alpha-1, which has actual regulatory recognition in several jurisdictions. The zinc-dependency biology and aging-thymus angle provide modest bench value but don’t overcome the compound’s age, weak differentiation, and thin human evidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Zinc-dependent thymic nonapeptide

A zinc-dependent endogenous thymic nonapeptide secreted by thymic epithelial cells with T-cell maturation activity.

Abstract

Thymulin (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn; molecular weight 857) is a nonapeptide originally isolated by Bach and Goldstein groups in the 1970s. The peptide is endogenously secreted by thymic epithelial cells and requires bound zinc for biological activity. Pharmacology includes promotion of T-cell differentiation, modulation of cytokine balance, and effects on autoimmune and inflammatory processes. The compound has been studied in chronic infections, autoimmune diseases, and cancer immunotherapy adjunct applications, with limited Phase 2 evidence. Available as research peptide. Doses are typically 100 to 1000 micrograms per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-128Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Reboxetine

Plain-language summaryIntrigue 55 / 100

Reboxetine, sold as Edronax in Europe (not FDA-approved), is a selective norepinephrine reuptake inhibitor (NRI). It was developed as an antidepressant; clinical evidence has been mixed. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

25/100

FDA-rejected selective NRI with documented publication bias and a weak, contested evidence base

Look, reboxetine has a real mechanism. NET inhibition is measurable, the selectivity profile is genuine, and the pharmacokinetics are reasonably clean at a 13-hour half-life with the (S,S)-enantiomer carrying most of the noradrenergic activity. We’re not saying it’s a fake compound. We’re saying it’s a compound where the important questions have been answered, and the answers weren’t encouraging.

The FDA rejection in 2001 was the first signal, but the real reckoning came in 2010 when Eyding et al. published their BMJ meta-analysis after obtaining unpublished trial data from Pfizer. The conclusion was stark: the published literature had significantly overestimated efficacy, the unpublished trials showed the compound was no better than placebo on the full dataset, and the benefit-to-risk picture for depression essentially collapsed. Thats not a mixed evidence situation. That’s a case where systematic publication bias produced a sustained false positive that shaped European prescribing for over a decade. The visible published record looked credible. The full record didn’t.

For bench research, the situation is slightly better but not compelling. Reboxetine can function as a selective NRI probe to isolate noradrenergic contributions in a given assay or behavioral model, and its selectivity for NET over SERT and DAT is well-characterized. The problem is atomoxetine serves the same role with more extensive preclinical literature, FDA approval in ADHD providing a legitimate pharmacological anchor, and broader commercial availability. As a tool, reboxetine is functional but not first-choice for most research programs doing serious noradrenergic work.

The mechanism itself, single-target NET inhibition, doesn’t generate the kind of questions that attract serious investigation right now. The frontier in noradrenergic biology is adrenergic receptor subtype pharmacology, locus coeruleus circuit dynamics, and NE’s role in stress-resilience and threat-appraisal circuits. Reboxetine can contribute peripherally to some of that work, but it’s not driving any active research program we’re aware of. When you check recent literature, it appears mostly as a comparator or a cautionary example of publication bias, not as the primary agent of interest.

What we don’t like: the evidence base is actively misleading if you read only the published record. Anyone designing a study that touches noradrenergic pharmacology and leans on pre-2010 reboxetine efficacy claims is making a methodological error. The Eyding analysis should be considered required reading before this compound enters any design. It’s available as a research chemical in several jurisdictions with straightforward sourcing, and honestly that may be the most practically useful thing we can say about it. The scientific return on investing bench time here is low, and better NRI probes exist if selective noradrenergic inhibition is the angle you need.

Novelty

20

Mechanism promise

22

In-category differentiation

28

Evidence quality

25

Translational signal

20

Research bench value

38

Rationale Reboxetine scores low primarily because the 2010 Eyding BMJ meta-analysis exposed systematic publication bias that inflated efficacy claims; the full Pfizer trial dataset shows no better than placebo for depression. NET inhibition is real and selective, but single-target and not novel, and atomoxetine provides a more credentialed NRI probe for bench work. Calculated overall of 25 sits well below any applicable structural cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective norepinephrine reuptake inhibitor

A selective NRI marketed in Europe as Edronax for depression but rejected by the FDA for inadequate efficacy.

Abstract

Reboxetine (Edronax; CAS 71620-89-8; molecular formula C19H23NO3; molecular weight 313.39) is a selective norepinephrine reuptake inhibitor approved in Europe (1997) for major depressive disorder. The FDA rejected the compound’s NDA for inadequate efficacy demonstration. The compound is marketed as the racemate; the (S,S)-enantiomer carries the majority of NET inhibition activity. Pharmacokinetics: plasma half-life 13 hours. Doses are 8 to 12 mg per day in two divided administrations. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-143Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Kanna (Sceletium tortuosum)

Plain-language summaryIntrigue 58 / 100

Kanna (Sceletium tortuosum) is a South African succulent traditionally fermented and chewed for mood and stress effects. The mesembrine alkaloids inhibit serotonin reuptake similar to SSRIs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

40/100

Dual SSRI-plus-PDE4 botanical with real Phase 2 data but modest effect sizes and limited bench utility

Look, Kanna is more interesting than it first appears, but that bar isnt high when you’re talking about a traditional South African botanical that’s been standardized into an OTC capsule. The SSRI activity via mesembrine is the part most people lead with, and its the part that matters least. Single-receptor serotonin reuptake inhibition in 2025 is a crowded, well-trodden space, and a botanical doing it modestly doesnt move the needle on research interest.

Here’s what actually warrants attention: mesembrenone’s PDE4 inhibition. PDE4 is a serious research target. Rolipram defined the pharmacology decades ago, and roflumilast’s approval validated it clinically. What’s interesting about Kanna is that you get dual activity in a single plant extract, SSRI-like serotonergic action alongside cAMP elevation through PDE4 blockade, and those two mechanisms can in principle produce effects that neither achieves alone. That’s a legitimate pharmacological question. It’s not paradigm-shifting, but it’s not trivial either.

The Zembrin studies are worth knowing. Terburg et al. (2013) showed amygdala-reactivity blunting on fMRI in healthy subjects at 25 mg standardized extract. That’s a real, objective readout, not a self-report questionnaire. A follow-up cognition study showed modest speed-of-processing gains under mild stressor conditions. The effect sizes are small, the N values are in the dozens, and most of the clinical work comes from a tight consortium with industry ties to the Zembrin IP. Thats a replication problem that keeps the evidence score depressed.

What we like: the PDE4 angle gives this actual probe value for anyone studying cAMP signaling alongside serotonergic modulation, a combination you cant easily achieve with separate tools without confounding variables. The fMRI amygdala work is a credible human translational signal. Sourcing of standardized extract is reliable. What we dont like: the research community hasn’t really picked this up outside of the Zembrin consortium work, there’s no serious multi-lab preclinical program building on the mechanism, and the alkaloid bioavailability data is thin. The PDE4 inhibition potency is also modest compared to rolipram as a reference tool.

Honestly, Kanna sits in an awkward space. It’s more pharmacologically interesting than cordyceps or basic adaptogens, but it’s not going to displace purpose-built PDE4 inhibitors or SSRIs as research tools. If your program specifically involves dual serotonergic-cAMP signaling in anxiety models, this is a compound worth knowing. For most other programs, it’s background reading.

Novelty

35

Mechanism promise

50

In-category differentiation

38

Evidence quality

35

Translational signal

42

Research bench value

35

Rationale Kanna earns its score primarily on the PDE4 inhibition angle via mesembrenone, which is a genuinely non-trivial mechanism in a botanical; the SSRI side is unremarkable. Zembrin trials provide real human signal but small N and modest effect sizes keep evidence and translational scores firmly in the 30s-40s, landing the overall at 40.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

South African botanical / SSRI-like alkaloids

A South African succulent containing mesembrine alkaloids with serotonin reuptake inhibition and PDE4 inhibition activities.

Abstract

Kanna (Sceletium tortuosum) is a succulent native to South Africa with traditional use for mood elevation and anxiety. Active constituents are mesembrine alkaloids (mesembrine, mesembrenone, mesembrenol). Pharmacology includes serotonin reuptake inhibition (mesembrine has SSRI-like activity) and phosphodiesterase 4 (PDE4) inhibition (mesembrenone), the latter providing anti-inflammatory and modest cognitive effects through cAMP elevation. The compound has been formulated as standardized extracts (Zembrin) and studied in small Phase 2 trials for anxiety with positive but modest results. Doses are typically 25 to 50 mg of standardized extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-175Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vortioxetine

Plain-language summaryIntrigue 75 / 100

Vortioxetine, sold as Trintellix, is a multimodal antidepressant approved by the FDA in 2013. It combines SERT inhibition with multiple serotonin receptor effects (5-HT1A agonism, 5-HT3 antagonism, and others), reportedly with cognitive benefits beyond typical SSRIs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

58/100

Multimodal serotonergic probe with real cognitive differentiation from SSRIs, but 2013 vintage limits novelty

Look, vortioxetine is genuinely interesting and we want to be fair to it. The multimodal serotonergic profile, serotonin transporter inhibition plus antagonism at 5-HT3 and 5-HT7 plus 5-HT1A agonism and partial 5-HT1B activity, was a real pharmacological step when Lundbeck and Takeda pushed it through in 2013. That’s not a me-too SSRI. The receptor polypharmacology generates downstream effects on glutamate and acetylcholine signaling that a straight SERT blocker can’t replicate, and thats where the cognitive story comes from.

The cognitive data is what keeps vortioxetine relevant. The FOCUS trial (2014, Mahableshwarkar et al.) was a reasonably well-designed RCT in MDD patients that showed improvements in executive function and processing speed that couldn’t be fully explained by mood improvement alone. That separation matters. Subsequent work, including the CONNECT study, has tried to pin down whether the cognitive effects are direct or mood-mediated, and the evidence leans toward a real if modest direct contribution. That makes it a useful pharmacological probe for asking how 5-HT3 and 5-HT7 modulation shapes prefrontal cognitive function independently of antidepressant response.

Here’s the thing though: it’s 2026, and this is a 2013 approval. The compound is characterized. The mechanism story has been told. Within the antidepressant space it is clearly differentiated, there really isn’t another approved drug with this receptor profile and independently documented cognitive outcomes, but best-in-class antidepressant with cognitive benefits in depressed patients is a narrower claim than it sounds. Researchers using it to study serotonergic cognition need to contend with MDD as a confound unless they’re specifically targeting that population.

What we like: the multimodal mechanism is a legitimate research handle. If you’re building a serotonin-cognition research program, vortioxetine is a more informative probe than any SSRI, and the approved-drug status means sourcing is clean with known pharmacokinetics and a well-defined safety envelope. What we don’t like: novelty is basically exhausted. The big mechanistic questions have been asked and largely answered. Phase 3 data exists, but it’s antidepressant-indication data; work in non-depressed populations or in aging or prodromal-dementia cohorts is thin enough that you’d be doing genuinely early work if you went that direction.

Honestly, for a research library targeting frontier compounds, vortioxetine sits in a useful-but-not-exciting middle tier. It’s worth holding if your program touches serotonergic cognition or MDD pharmacology, but you’d reach for it as supporting infrastructure rather than a primary investigation target. Real mechanism, real evidence, real differentiation from SSRIs, not enough novelty remaining to push it anywhere near the upper tier.

Novelty

38

Mechanism promise

62

In-category differentiation

60

Evidence quality

73

Translational signal

68

Research bench value

52

Rationale Vortioxetine’s receptor polypharmacology (SERT plus 5-HT3/7 antagonism plus 5-HT1A agonism) and documented cognitive outcomes in dedicated RCTs give it genuine differentiation from SSRIs and real bench utility for serotonin-cognition research; however, twelve years post-approval and thorough mechanistic characterization leave little frontier territory, keeping novelty scores low and placing the overall in the upper-established tier rather than anything approaching frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Multimodal serotonergic antidepressant

A multimodal serotonergic antidepressant (Trintellix) FDA-approved 2013 with documented cognitive benefits in addition to mood effects.

Abstract

Vortioxetine (Trintellix, Brintellix; CAS 508233-74-7; molecular formula C18H22N2S; molecular weight 298.45) is a multimodal serotonergic antidepressant developed by Lundbeck and Takeda and approved by the FDA in 2013 for major depressive disorder. Mechanism includes serotonin reuptake inhibition (SERT), 5-HT3 antagonism, 5-HT7 antagonism, 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT1D antagonism. The combination produces a clinical profile with antidepressant efficacy plus documented improvements in cognitive function (executive function, processing speed) that are distinct from typical SSRI cognitive profiles. Approved doses are 5 to 20 mg per day. Generally well tolerated.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-191Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Venlafaxine

Plain-language summaryIntrigue 64 / 100

Venlafaxine (Effexor) was the first dual-action antidepressant, hitting both the serotonin and norepinephrine pumps in the same molecule. Wyeth got it approved in 1993. The catch is that the dual action depends on dose: at low doses it acts mostly like an SSRI; the norepinephrine effect only kicks in meaningfully above roughly 150 mg per day. The active leftover after the liver works on it does most of the heavy lifting at steady state, and that leftover is itself sold separately as desvenlafaxine. It has a notoriously brutal discontinuation profile because its half-life is short and patients feel every missed dose. Approved for depression, generalized anxiety, social anxiety, and panic disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

The prototype SNRI; well-evidenced clinical drug with a settled mechanism and low bench-scale research novelty

Look, venlafaxine is the prototype SNRI. FDA approved in 1993, it was the first compound to demonstrate that adding noradrenergic reuptake inhibition on top of serotonergic blockade produced a meaningfully different clinical profile. That was actually interesting, in 1993. The dose-dependent transporter selectivity, predominantly serotonergic below 150 mg and genuinely dual-action above that threshold, gave pharmacologists a clean handle to study SERT/NET engagement ratios and established the template that duloxetine, milnacipran, levomilnacipran, and desvenlafaxine all followed.

The problem is thats 33 years of problem-solving. The mechanistic story is settled. The clinical evidence is massive and replicated across dozens of RCTs and meta-analyses covering depression, generalized anxiety, social anxiety, and neuropathic pain. The indication map is fully drawn. You can pull the venlafaxine pharmacology from a 2003 textbook and still be current in 2026. When a compound’s review papers lead with “as established in the original Wyeth trials”, thats not where you want to be as a bench investigator looking for signal.

We do credit it as a reference tool. If you’re building a dual-action antidepressant platform and need a positive control with clean pharmacokinetics and a well-characterized metabolic profile (CYP2D6 primary, CYP3A4 secondary, desvenlafaxine as the major active metabolite), venlafaxine is a reasonable anchor. The short parent half-life of approximately 5 hours, paired with the metabolite’s longer window of roughly 11 hours, also makes it a useful pharmacokinetic model for studying discontinuation biology and the temporal dynamics of dual-transporter withdrawal. Niche, but legitimate, and its why bench value isn’t zero here.

What we don’t like: the class is saturated and the alternatives are better on almost every research axis. Duloxetine has broader regulatory indications and cleaner tolerability data in comparative trials. Levomilnacipran has stronger NET selectivity if thats your target. Desvenlafaxine, the active metabolite, is now its own approved drug with its own literature. If you’re trying to probe SNRI pharmacology, you have more specific tools for nearly every question venlafaxine might answer, and most of them were designed to answer it better.

Honestly, the compound scores where it scores not because it’s ineffective; it’s a well-validated drug with a clear clinical footprint. It scores low because the research conversation has moved on. The mechanism is understood, the class is full, and the frontier questions in monoaminergic neuroscience, sigma-1 receptor involvement, neuroinflammatory crosstalk, predictive response biomarkers, are being answered with newer, purpose-built probes. Venlafaxine belongs in the reference library. It does not belong on the priority list.

Novelty

12

Mechanism promise

28

In-category differentiation

22

Evidence quality

78

Translational signal

75

Research bench value

45

Rationale Venlafaxine scores high on evidence and translational signal (approved drug, massive RCT base, replicated across indications) but near-rock-bottom on novelty and differentiation; the SNRI class is saturated, the mechanism is textbook, and newer alternatives answer almost every research question more cleanly. Overall 40 reflects a drug that works but offers no frontier for a serious bench investigator.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin-norepinephrine reuptake inhibitor

A bicyclic SNRI with dose-dependent transporter selectivity; the prototype dual-action antidepressant.

Abstract

Venlafaxine ((R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CAS 93413-69-5; molecular formula C17H27NO2; molecular weight 277.40) is a bicyclic phenethylamine SNRI developed at Wyeth and approved by the FDA in 1993 under the trade name Effexor. The compound is the prototype clinical SNRI, exhibiting dose-dependent transporter selectivity: at doses below 150 mg daily it functions as an SSRI (SERT inhibition predominates with NET inhibition becoming clinically meaningful only at higher doses); at 150 to 375 mg daily, NET engagement adds a noradrenergic component. The active metabolite O-desmethylvenlafaxine (desvenlafaxine, marketed separately as Pristiq) carries comparable transporter activity and contributes substantially to the steady-state effect. Plasma half-life of the parent compound is approximately 5 hours; the metabolite half-life is approximately 11 hours. Metabolism is via CYP2D6 (primary) and CYP3A4 (secondary). The compound exhibits a pronounced discontinuation syndrome, attributed to the short half-life and combined serotonergic-noradrenergic withdrawal. Used as the reference SNRI in mechanism studies and as a positive control in dual-action antidepressant pharmacology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-207Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 54 55 56 57 58 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.